Wealthfront Advisers
ZBH icon

Wealthfront Advisers’s Zimmer Biomet ZBH Stock Holding History

Wealthfront Advisers’s Portfolio ZBH Stock Details ZBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$812K Sell
9,430
-3,831
-29% -$336K ﹤0.01% 759
2026
Q1 		$1.2M Buy
13,261
+3,606
+37% +$331K ﹤0.01% 687
2025
Q4 		$868K Buy
9,655
+385
+4% +$36.5K ﹤0.01% 733
2025
Q3 		$913K Buy
9,270
+4,393
+90% +$435K ﹤0.01% 708
2025
Q2 		$445K Buy
4,877
+1,074
+28% +$104K ﹤0.01% 817
2025
Q1 		$430K Buy
3,803
+1,030
+37% +$110K ﹤0.01% 801
2024
Q4 		$293K Sell
2,773
-449
-14% -$48.2K ﹤0.01% 839
2024
Q3 		$348K Sell
3,222
-492
-13% -$53.7K ﹤0.01% 817
2024
Q2 		$403K Sell
3,714
-1,268
-25% -$149K ﹤0.01% 768
2024
Q1 		$658K Buy
4,982
+693
+16% +$86.6K ﹤0.01% 692
2023
Q4 		$522K Sell
4,289
-3,041
-41% -$339K ﹤0.01% 712
2023
Q3 		$823K Sell
7,330
-1,042
-12% -$132K ﹤0.01% 597
2023
Q2 		$1.22M Buy
8,372
+30
+0.4% +$4.08K 0.01% 518
2023
Q1 		$1.08M Sell
8,342
-1,060
-11% -$133K ﹤0.01% 511
2022
Q4 		$1.2M Buy
9,402
+708
+8% +$82.2K 0.01% 484
2022
Q3 		$909K Buy
8,694
+4,814
+124% +$528K ﹤0.01% 496
2022
Q2 		$408K Sell
3,880
-1,621
-29% -$192K ﹤0.01% 628
2022
Q1 		$703K Buy
5,501
+1,325
+32% +$160K ﹤0.01% 574
2021
Q4 		$515K Buy
4,176
+1,056
+34% +$138K ﹤0.01% 588
2021
Q3 		$444K Buy
3,120
+196
+7% +$28.8K ﹤0.01% 577
2021
Q2 		$457K Sell
2,924
-376
-11% -$60.9K ﹤0.01% 532
2021
Q1 		$513K Buy
3,300
+416
+14% +$64.4K ﹤0.01% 457
2020
Q4 		$431K Buy
2,884
+33
+1% +$4.66K ﹤0.01% 454
2020
Q3 		$377K Buy
2,851
+256
+10% +$33.4K ﹤0.01% 435
2020
Q2 		$301K Buy
+2,595
New +$299K ﹤0.01% 452
2020
Q1 		– Sell
-2,294
Closed -$333K – 502
2019
Q4 		$333K Buy
2,294
+188
+9% +$26K ﹤0.01% 442
2019
Q3 		$281K Buy
2,106
+148
+8% +$19.1K ﹤0.01% 434
2019
Q2 		$224K Sell
1,958
-232
-11% -$27.2K ﹤0.01% 467
2019
Q1 		$271K Buy
+2,190
New +$249K ﹤0.01% 436

Other funds holding ZBH

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wealthfront Advisers's ZBH Position: Q2 2026 in Review

Wealthfront Advisers reduced its Zimmer Biomet (ZBH) stake by 29% in Q2 2026, selling an estimated $336K and leaving 9,430 shares worth $812K. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Wealthfront Advisers first reported a position in ZBH in Q1 2019 and has held it in 29 quarters since. The position peaked at $1.22M in Q2 2023. 906 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.

  • Wealthfront Advisers held 9,430 shares of Zimmer Biomet worth $812K as of Q2 2026.
  • Wealthfront Advisers sold 3,831 Zimmer Biomet shares in Q2 2026, an estimated $336K.
  • Zimmer Biomet made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #759 holding.
  • Wealthfront Advisers first reported a position in Zimmer Biomet in Q1 2019 and has held it in 29 quarters since.
  • Wealthfront Advisers's Zimmer Biomet position peaked at $1.22M in Q2 2023.
  • 906 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.